RX Alerts

Striking Savings Are Possible (But Your Plan Needs To Act To Obtain Them)

We’re thrilled to report that yet another Coalition Member that followed our Coalition’s recommendations and took aggressive steps to control its prescription coverage costs has now achieved a 16% cost decrease.

Sound too good to be true?

Go here to learn what the Coalition Member did to achieve these savings, and how you can do so as well.

Pull Back the Curtain on Manufacturers’ and Switch Operators’ Efforts To Undermine Your Plan’s Cost Savings Efforts

Like most health plans, your plan may be doing  all it can to steer your plan beneficiaries to use lower-cost drugs. But manufacturers are paying switch operators (like Relay Health and Change Healthcare) to foil your efforts.

If you don’t know what switch operators are or what they do – or your plan is not taking steps to counter switch operators’  machinations – you need to read this article.

Don’t Be Fooled By Eli Lilly’s & Express Scripts’ New Diabetes Program

In December 2016, Eli Lilly and Express Scripts announced a new diabetes treatment program to provide 40% discounts on three Lilly diabetes drugs. But the program is anything unknown-1but what it appears.

We explain why in this article, and provide recommendations for health plans and our media friends.

Don’t Be Duped By Manufacturers’ Single Digit Price Increase Pledges

Two manufacturers – Allergan and Novo Nordisk – recently won headlines when each vowed to limit the images-1company’s annual drug price increases to single digit numbers. But such increases are anything but laudatory. We explain why in this article.

Message from Mylan: Pay Attention to Rebates

In recent testimony before a th-1House Committee, Mylan’s CEO asserted that $334 of EpiPen’s list price of $608 – or 55% of the total $608 – could be attributed to PBMs and three other drug channel vendors extracting payments from Mylan.

Soon, other evidence emerged reflecting manufacturers’ price increases related to diabetes and rheumatoid arthritis drugs might be related to PBMs’ rebate activities.

These new developments make clear that every Plan administrator needs to understand the complex world of drug manufacturer rebates and other payments, and develop strategies that will address these issues. Go here to do so.

Take Action To Decrease Your Plan’s Crestor Costs

If you examine your Heath Plan’s claims data, it’s extremely likely you’ll discover that Crestor is costing your Plan a small fortune.

Typically, Crestor represents more ththan 1% of a Plan’s total annual drug costs. As a result, Crestor almost always appears on a Plan’s list of “Top Twenty Most Expensive Drugs.” Frequently, Crestor is among the “Top Ten” – jockeying to collect even more money from Plans than many high-cost specialty drugs.

But as if manna has fallen from heaven, there is now a means to reduce your Health Plan’s costs. Details can be found in this article.